A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Study Summary

A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration

Conditions

Geographic Atrophy Secondary to Age-related Macular Degeneration

Interventions / Drugs

APL-3007, pegcetacoplan (APL-2)APL-3007, pegcetacoplan (APL-2)Placebo, Syfovre

View on ClinicalTrials.gov ↗

Sponsor

APLS

Apellis Pharmaceuticals

Complement Inhibitors

D36/100

Study Details

Enrollment240 participants

Primary Completion—

Lead SponsorApellis Pharmaceuticals, Inc.

Data Retrieved2026-04-11 02:54:08.046067+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.